Cytokinetics, Inc. (CYTK)

[H2R]

Estimated Completion Date: Jul. 2017 for VITALITY-ALS / NCT02496767

This Phase III Trial is not the one discussed on the Feb. 2 PR. The NCT02496767 / VITALITY-ALS Estimated Completion Date is July 2017, so data sometime after that, most likely this year.

Then a follow up, NCT02936635 to the Phase 3 has already started; It is open to the NCT02496767 / VITALITY-ALS and that will take another 3 years potentially, unless AE's unfortunately shorten the follow up.
"A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)" with an estimated completion date of October 2019 .